MX336476B - Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. - Google Patents
Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado.Info
- Publication number
- MX336476B MX336476B MX2012001745A MX2012001745A MX336476B MX 336476 B MX336476 B MX 336476B MX 2012001745 A MX2012001745 A MX 2012001745A MX 2012001745 A MX2012001745 A MX 2012001745A MX 336476 B MX336476 B MX 336476B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- breast cancer
- previously treated
- angiogenesis therapy
- treated breast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
- G06Q30/0251—Targeted advertisements
- G06Q30/0269—Targeted advertisements based on user profile or attribute
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for specific business sectors, e.g. utilities or tourism
- G06Q50/10—Services
- G06Q50/22—Social work
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
La presente invención se refiere a un anticuerpo anti-VEGF en la manufactura de un medicamento para tratar a un paciente diagnosticado con cáncer de mama triple negativo metastásico previamente tratado, en donde el paciente debió haber recibido una quimioterapia para la enfermedad metastásica en un tratamiento de primera línea, en donde el paciente es sometido a un régimen de tratamiento que combina una quimioterapia como una terapia de segunda línea para tratar el cáncer de mama metastásico previamente tratado con la administración de una cantidad efectiva de un anticuerpo anti-VEGF, que comprende una región variable de cadena pesada que tiene la siguiente secuencia de aminoácidos (SEQ ID NO. 1), y una región variable de cadena ligera que comprende la siguiente secuencia de aminoácidos: (SEQ ID NO. 2), en donde la quimioterapia del régimen de tratamiento en la terapia de segunda línea comprende la administración de al menos un agente quimioterapéutico, seleccionado del grupo que consiste en terapia con taxano, capecitabina, gemcitabina y vinorelbina, y en donde el régimen de tratamiento extiende efecgtivamente la supervivencia libre de progreso del paciente.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23428109P | 2009-08-15 | 2009-08-15 | |
| US26634309P | 2009-12-03 | 2009-12-03 | |
| PCT/US2010/045147 WO2011022264A1 (en) | 2009-08-15 | 2010-08-11 | Anti-angiogenesis therapy for the treatment of previously treated breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012001745A MX2012001745A (es) | 2012-03-21 |
| MX336476B true MX336476B (es) | 2016-01-20 |
Family
ID=42830354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012001745A MX336476B (es) | 2009-08-15 | 2010-08-11 | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20110047103A1 (es) |
| EP (2) | EP3090758A1 (es) |
| JP (2) | JP6088246B2 (es) |
| KR (1) | KR20120107069A (es) |
| CN (1) | CN102573909A (es) |
| AR (1) | AR077848A1 (es) |
| AU (2) | AU2010284446A1 (es) |
| BR (1) | BR112012003346A2 (es) |
| CA (1) | CA2771086A1 (es) |
| CL (1) | CL2012000387A1 (es) |
| CO (1) | CO6612209A2 (es) |
| CR (1) | CR20120076A (es) |
| IL (1) | IL218007A0 (es) |
| MA (1) | MA33579B1 (es) |
| MX (1) | MX336476B (es) |
| NZ (1) | NZ598131A (es) |
| RU (1) | RU2576027C2 (es) |
| SG (2) | SG178419A1 (es) |
| TW (2) | TWI451875B (es) |
| WO (1) | WO2011022264A1 (es) |
| ZA (1) | ZA201200998B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
| LT3423105T (lt) * | 2016-03-02 | 2021-09-10 | Eisai R&D Management Co., Ltd. | Antikūno-vaisto konjugatai eribulino pagrindu ir jų panaudojimo būdai |
| CN111050784B (zh) * | 2017-08-11 | 2024-03-19 | 伊利诺伊大学理事会 | 截短的豚鼠l-天冬酰胺酶变体及其使用方法 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2145985C (en) | 1992-10-28 | 2003-09-16 | Napoleone Ferrara | Vascular endothelial cell growth factor antagonists |
| CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
| US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| EP0973804B1 (en) * | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
| EP3260468A1 (en) | 1997-04-07 | 2017-12-27 | Genentech, Inc. | Anti-vegf antibodies |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| EP1189641B1 (en) * | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| ATE337403T1 (de) | 1999-12-24 | 2006-09-15 | Genentech Inc | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
| ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| US20070065449A1 (en) * | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| US20100112077A1 (en) * | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
-
2010
- 2010-08-11 WO PCT/US2010/045147 patent/WO2011022264A1/en active Application Filing
- 2010-08-11 AU AU2010284446A patent/AU2010284446A1/en not_active Abandoned
- 2010-08-11 KR KR1020127006656A patent/KR20120107069A/ko not_active Application Discontinuation
- 2010-08-11 CN CN2010800464523A patent/CN102573909A/zh active Pending
- 2010-08-11 EP EP16171215.3A patent/EP3090758A1/en not_active Withdrawn
- 2010-08-11 MX MX2012001745A patent/MX336476B/es unknown
- 2010-08-11 SG SG2012010377A patent/SG178419A1/en unknown
- 2010-08-11 TW TW099126812A patent/TWI451875B/zh active
- 2010-08-11 RU RU2012109932/15A patent/RU2576027C2/ru active
- 2010-08-11 SG SG2013073556A patent/SG194395A1/en unknown
- 2010-08-11 JP JP2012524835A patent/JP6088246B2/ja active Active
- 2010-08-11 AR ARP100102939 patent/AR077848A1/es unknown
- 2010-08-11 US US12/854,711 patent/US20110047103A1/en not_active Abandoned
- 2010-08-11 TW TW102139989A patent/TW201431558A/zh unknown
- 2010-08-11 EP EP10747115A patent/EP2464381A1/en not_active Withdrawn
- 2010-08-11 NZ NZ598131A patent/NZ598131A/en not_active IP Right Cessation
- 2010-08-11 BR BR112012003346A patent/BR112012003346A2/pt active Search and Examination
- 2010-08-11 CA CA2771086A patent/CA2771086A1/en not_active Abandoned
-
2012
- 2012-02-09 IL IL218007A patent/IL218007A0/en unknown
- 2012-02-10 ZA ZA2012/00998A patent/ZA201200998B/en unknown
- 2012-02-14 CR CR20120076A patent/CR20120076A/es unknown
- 2012-02-14 CL CL2012000387A patent/CL2012000387A1/es unknown
- 2012-02-20 CO CO12029506A patent/CO6612209A2/es unknown
- 2012-03-12 MA MA34681A patent/MA33579B1/fr unknown
-
2014
- 2014-11-17 US US14/543,588 patent/US20150071924A1/en not_active Abandoned
-
2015
- 2015-12-10 JP JP2015240828A patent/JP2016117718A/ja active Pending
-
2016
- 2016-05-09 AU AU2016202976A patent/AU2016202976A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201431558A (zh) | 2014-08-16 |
| JP2013501801A (ja) | 2013-01-17 |
| JP2016117718A (ja) | 2016-06-30 |
| MX2012001745A (es) | 2012-03-21 |
| BR112012003346A2 (pt) | 2016-11-16 |
| WO2011022264A1 (en) | 2011-02-24 |
| AR077848A1 (es) | 2011-09-28 |
| SG178419A1 (en) | 2012-04-27 |
| TWI451875B (zh) | 2014-09-11 |
| RU2576027C2 (ru) | 2016-02-27 |
| RU2012109932A (ru) | 2013-09-20 |
| US20110047103A1 (en) | 2011-02-24 |
| JP6088246B2 (ja) | 2017-03-01 |
| AU2016202976A1 (en) | 2016-05-26 |
| EP3090758A1 (en) | 2016-11-09 |
| CR20120076A (es) | 2012-05-29 |
| TW201109032A (en) | 2011-03-16 |
| ZA201200998B (en) | 2013-05-29 |
| MA33579B1 (fr) | 2012-09-01 |
| KR20120107069A (ko) | 2012-09-28 |
| AU2010284446A1 (en) | 2012-03-08 |
| CL2012000387A1 (es) | 2012-10-05 |
| CO6612209A2 (es) | 2013-02-01 |
| IL218007A0 (en) | 2012-04-30 |
| EP2464381A1 (en) | 2012-06-20 |
| CA2771086A1 (en) | 2011-02-24 |
| US20150071924A1 (en) | 2015-03-12 |
| NZ598131A (en) | 2014-08-29 |
| SG194395A1 (en) | 2013-11-29 |
| CN102573909A (zh) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501728A1 (en) | Anti-angiogenesis therapy for the treatment of ovarian cancer | |
| PH12014502507A1 (en) | Anti-angiogenesis therapy for the treatment of breast cancer | |
| RS20150135A1 (en) | TREATMENT WITH ANTI-VEGF ANTIBODIES | |
| MX2019012462A (es) | Terapia combinada. | |
| EA201791876A1 (ru) | Моноклональные антитела к прогастрину и их применение | |
| MX360984B (es) | Anticuerpos monoclonales para el uso en la diagnosis y la terapia de cánceres y de enfermedades autoinmunes. | |
| MX2019006331A (es) | Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos. | |
| WO2015049688A3 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| WO2012145535A3 (en) | Animal model of human cancer and methods of use | |
| WO2012170513A3 (en) | He4 based therapy for malignant disease | |
| MX2021005761A (es) | Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados. | |
| MX2012001745A (es) | Terapia anti-angiogenesis para el tratamiento de cancer de mama previamente tratado. | |
| MX2011004979A (es) | N-cadherina:blanco para diagnosis y terapia de cancer. | |
| MX2018009499A (es) | Anticuerpos monoclonales especificos de egfl6 y metodos de su uso. | |
| MX2023007706A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
| WO2009091230A3 (ko) | 유방암 모니터링,진단 및 스크리닝용 단백질 마커 및 이를 이용한 유방암 모니터링,진단 및 스크리닝 방법 | |
| MX2014002762A (es) | Uso de proteina c-met para predecir la eficacia de anticuerpos de factor de crecimiento de anti-hepatocitos (hgf) en pacientes con cancer esofagico y gastrico. | |
| MX2015006096A (es) | Leucocitos como celulas de administracion para imagen y terapia de enfermedad. | |
| MX2021011799A (es) | Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer. | |
| PH12015502516A1 (en) | Efficacious treatment of nsclc and predictive clinical marker of the responsiveness of a tumour to a treatment | |
| MX2012003287A (es) | Uso de la identificacion microambiental de sparc en el tratamiento del cancer. | |
| AU2018256601A1 (en) | Use of anti-VEGF antibody in combination with chemotherapy for treating breast cancer | |
| PL423203A1 (pl) | Czynnik wzrostu do zastosowania w terapii przeciwnowotworowej dla pacjentów z nowotworami, w których przynajmniej część komórek wykazuje ekspresję EGFRvIII | |
| RU2010105466A (ru) | Способ лечения онкологических заболеваний |